Adial Pharmaceuticals Inc (ADIL) - News Archive

In a significant advancement in the treatment of alcohol use disorder (AUD), Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), a clinical-stage biopharmaceutical company, recently reported positive topline results from its AD...

Overview of Financial PerformanceAdial Pharmaceuticals, Inc. (NASDAQ: ADIL), a pioneering biopharmaceutical firm based in Glen Allen, Virginia, recently published its financial results for the third quarter of 2024 and...

Advancements in Alcohol Use Disorder Treatment: Adial Pharmaceuticals and the Evolving Landscape of Recovery DefinedIn a pivotal moment for the treatment of Alcohol Use Disorder (AUD), Adial Pharmaceuticals is at the fo...

Adial Pharmaceuticals Advances Precision Medicine Approach for Alcohol Use Disorder with Promising Developments in AD04 Clinical Trials and ResearchAdial Pharmaceuticals is making significant strides in the field of pre...

GLEN ALLEN, Va. Sept. 04, 2024 Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for the treatment and prevention of addiction and relate...

Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use DisorderAdial Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the development of...

Precision Medicine for Alcohol Use Disorder: Promising Efficacy of AD04 : Recent findings suggest that AD04, a potential precision medicine targeting Alcohol Use Disorder (AUD), significantly reduces heavy drinking days...

Adial Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing therapies for addiction and related disorders, recently reached a significant milestone by successfully dosing the first patient...

Adial Pharmaceuticals, a prominent player in the medical industry, recently released a peer-reviewed publication that emphasizes the promising safety data and high patient compliance rates in a clinical trial of AD04, a...

Adial Pharmaceuticals, a clinical-stage biopharmaceutical company focusing on addiction therapeutics, has recently announced the receipt of the final development cost reimbursement payment of $350,000 from Adovate, LLC....

Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Rule, Strengthens Position in Addiction Treatment MarketCharlottesville, Va. - Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmace...